U 92016A

Cat. No. 2739 Datasheet / COA / SDS

Discontinued Product

Unfortunately U 92016A (Cat. No. 2739) has been withdrawn from sale for commercial reasons.
Cat.No. 2739 - U 92016A | C19H25N3.HCl | CAS No. 149654-41-1
Description: Selective 5-HT1A agonist
Chemical Name: (8R)-8-(Dipropylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-2-carbonitrile hydrochloride
Purity: ≥99% (HPLC)
Datasheet
Citations
Reviews
Literature

Biological Activity

Selective 5-HT1A receptor agonist that displays high intrinsic activity (Ki values are 0.4, 7.7 and 36 nM for 5-HT1A, 5-HT1D and D2 receptors respectively and > 1000 nM for 5-HT2, D1, α1 and α2 receptors). Produces hypothermia, hypotension and 5-HT behavioral syndrome following p.o. administration.

Technical Data

M. Wt 331.88
Formula C19H25N3.HCl
Storage Desiccate at RT
Purity ≥99% (HPLC)
CAS Number 149654-41-1
Smiles CCCN(CCC)[C@@H]1CCC(C=CC3=C2C=C(C#N)N3)=C2C1.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Product Datasheets

Safety Datasheet

References

References are publications that support the products' biological activity.

Romero et al (1993) Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants. J.Med.Chem. 36 2066 PMID: 8101876

McCall et al (1994) Characterization of U-92016A as a selective, orally active, high intrinsic activity 5-hydroxytryptamine1A agonist. J.Pharmacol.Exp.Ther. 271 875 PMID: 7965808

View Related Products by Target

View Related Products by Product Action

View all 5-HT1A Receptor Agonists

Keywords: U 92016A, supplier, Selective, 5-HT1A, agonists, Serotonin, Receptors, U92016A, 5-HT1A, Receptors, 5-HT1A, Receptors, Tocris Bioscience

Citations for U 92016A

Citations are publications that use Tocris products.

Currently there are no citations for U 92016A.

Reviews for U 92016A

There are currently no reviews for this product. Be the first to review U 92016A and earn rewards!

Have you used U 92016A?

Submit a review and receive an Amazon gift card.

$10US/$10CAN/€7/£6 gift card for a review without an image

$25US/$25CAN/€18/£15 gift card for a review with an image

*Offer only valid in the USA / Canada, UK and Europe

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
5-HT Receptors

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.